DIPROLENE 0.05% price in UAE

Overview

Welcome to Dwaey, specifically on DIPROLENE 0.05% Cream page.
This medicine contains an important and useful components, as it consists of Betamethasone (as dipropionate).
DIPROLENE 0.05% is available in the market in concentration 0.5mg/g and in the form of Cream.

SCHERING-PLOUGH LABO N.V. is the producer of DIPROLENE 0.05% and it is imported from BELGIUM, The most popular alternatives of DIPROLENE 0.05% are listed downward .

Mode Of Action

Betamethasone is a corticosteroid with mainly glucocorticoid activity. It prevents and controls inflammation by controlling the rate of protein synthesis, depressing the migration of polymorphonuclear leukocytes and fibroblasts, and reversing capillary permeability and lysosomal stabilisation.

Indication

Ulcerative colitis
Rheumatoid arthritis
Ankylosing spondylitis
Lichen planus
Psoriasis
Asthma
Eczema
Contact dermatitis
Multiple sclerosis
Drug hypersensitivity reactions
Perennial or seasonal allergic rhinitis
Serum sickness
Transfusion reactions
Severe erythema multiforme (Stevens-Johnson syndrome)
Leukemias
Lymphomas
Acute gouty arthritis
Acute rheumatic carditis
Psoriatic arthritis
Including juvenile rheumatoid arthritis
Dermatomyositis
Polymyositis
Systemic lupus erythematosus
Psoriatic plaques
Allergic and inflammatory disorders
Congenital adrenal hyperplasia

Precaution

Uncontrolled diabetes, peptic ulcer, osteoporosis, psychosis, psychoneurosis, pregnancy and lactation. Congestive heart failure, hypertension, epilepsy, CRF, elderly, regular monitoring of patients on long term therapy, withdraw gradually, glaucoma, hypothyroidism, cirrhosis, ocular herpes simplex, ulcerative colitis, infants and children. Lactation: systemically administered corticosteroids enter breast milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other effects; use with caution

Side Effects

>10% (selected) Blurred vision
Increased appetite
Indigestion
Nervousness 1-10% Itching Frequency Not Defined (selected) Arthralgia
Cataracts
Dizziness
DM
Edema
Headache
Seizure
Vertigo
Fluid/electrolyte disturbances
Adrenal suppression
Psychosis
Insomnia
Pseudotumor cerebri (on withdrawal)
Acne
Osteoporosis
Myopathy
Delayed wound healing Potentially Fatal: Abrupt withdrawal leading to acute adrenal insufficiency manifesting as malaise
weakness
mental changes
muscle and joint pains
dystonia
hypoglycaemia
hypotension
dehydration and death. Rapid IV inj may cause CV collapse.

Contra indication

Hypersensitivity; systemic fungal or acute infections.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Increased hyperglycaemia and hypokalaemia with thiazide diuretics. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents. Potentially Fatal: Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Enhanced effect in women taking oestrogens or oral contraceptives.